Post-Deployment Screening Has Limited Benefit in U.K. Military

This article originally appeared here.
Share this content:
Post-Deployment Screening Has Limited Benefit in U.K. Military
Post-Deployment Screening Has Limited Benefit in U.K. Military

MONDAY, Feb. 20, 2017 (HealthDay News) -- Post-deployment screening for mental disorders is not effective for reducing the prevalence of posttraumatic stress disorder (PTSD), depression, anxiety, or alcohol misuse among U.K. military personnel, according to a study published online Feb. 16 The Lancet.

Roberto J. Rona, from the King's Center for Military Health Research in London, and colleagues randomized 434 platoons with 10,190 personnel to a screening group, which received tailored help-seeking advice, or to a control group, which received general mental health advice. Participants were assessed six to 12 weeks after deployment and underwent follow-up assessment 10 to 24 months later.

Eighty-eight percent of 6,350 personnel received screening and 63 percent completed follow-up, while 82 percent of 3,840 received the control questionnaire and 62 percent completed follow-up. The researchers found that, overall, 35 percent of personnel in the screening groups declined the tailored advice; those with PTSD or anxiety or depression were more likely to view the tailored advice than non-cases (83 and 84 percent, respectively, versus 64 percent; both P < 0.0001). There were no significant between-group differences in prevalence for PTSD, depression or anxiety, alcohol misuse, or seeking support for mental disorders.

"Post-deployment screening for mental disorders based on tailored advice was not effective at reducing prevalence of mental health disorders nor did it increase help-seeking," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »